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ABSTRACT 
 
 
As opposed to the petro-chemical and bulk chemical industry, where continuous 
processes are widely applied, the pharmaceutical industry still primarily relies on 
traditional batch process due to the complexity of product, multi-step operation and low-
volume production. Considering these conditions, the versatile batch process is more 
appropriate.  
Nowadays, driven by the contradiction between increasing demand for drugs and 
inefficient batch production mode, there is a trend in pharmaceutical industry, that is the 
transformation from traditional batch process to novel continuous process. Related 
projects and research that is aimed at analyzing this transition are conducted in worldwide, 
and the scale of these studies ranges from lab-scale reactions to overall arrangement of the 
factories.  
Although continuous pharmaceutical process is thriving, the safety issue in this field 
is not promoted at the same time. Since the continuous pharmaceutical process is a novel 
technology, little information can be provided to evaluate its safety level. Moreover, 
process conditions are usually intensified for continuous process comparing to batch 
process. It also may bring potential risks and make continuous manufacturing 
inappropriate for some of pharmaceutical productions. 
This research provides a comprehensive comparison for batch versus continuous 
pharmaceutical process by application of Dow’s Fire and Explosion Index. In addition to 
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this conventional safety evaluation, influences from production efficiency and specialties 
in pharmaceutical production are integrated into the comparison. Production of 2-methyl 
benzimidazole and peracetic acid via batch and continuous processes are conducted in this 
research. In these integrative and systematic studies, F&EI values for both cases are higher 
for continuous processes than batch processes, hence the higher safety level of the 
continuous process is demonstrated. The ways in which process conditions, production 
efficiency, and other requirements influence safety level for different production modes 
are illustrated.  
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1. INTRODUCTION  
 
Continuous process is widely applied in petro-chemical and bulk chemical industry 
for its high production rate, automated operation and saving in cost (Plumb, 2005). In 
contrast, the pharmaceutical industry still primarily relies on traditional batch process. 
This aspect stems from intrinsic limitations in active pharmaceutical ingredients (APIs) 
production. Complexity of medical substances means multistep synthesis. An average of 
8.1 steps is needed for one API synthesis (Laird, 2006). Another limitation is production 
volume. Demand for drugs are not comparable with most of the bulk chemicals. These 
limitations make batch process dominate pharmaceutical industry for a long time. 
However, due to the gradual expansion of the pharmaceutical market, batch process 
is behind the time because of its low production rate caused by low yield and inefficient 
operation mode. Driven by this contradiction between increasing demand for drugs and 
inefficient production mode, many pharmaceutical manufacturers are trying to shift from 
a traditional batch process to a novel continuous process. Experimental and industrial trials 
that are aimed at this transitioning have been done and exhibit the practicability of this 
new production mode. Several companies such as Lonza, Phoenix Chemical, and Corning 
make significant progress in this area (Braune et al., 2009; Proctor & Warr, 2002; 
Dominique et al., 2009). Novel continuous process exhibits great potential for the 
pharmaceutical industry. 
“Which process should be applied?” and “Is there enough benefit to move forward?” 
are the questions that are raised when an innovative process is introduced. To answer these 
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questions, comprehensive comparison between batch process and continuous process is 
required.  
This comparison should be specific in the early stages. For example, for a given 
substance, based on its intrinsic properties and demand in market, reasonable comparison 
is required to make a selection between batch and continuous process. After composing a 
conclusive summary that is based on number of different specific cases, the result of these 
comparisons can be modified and applied to generate a practical process screening 
methodology.  
For the questions mentioned above, economic benefits, safety and environmental 
impacts should all be considered to get a reliable answer. In the batch versus continuous 
process comparisons, related economic analysis and environmental analysis have been 
done by many researchers (Hessel et al., 2012; Jolliffe & Gerogiorgis, 2016; Spencer et 
al., 2011). However, there remains gaps in research and understanding of safety 
considerations in comparison of batch versus continuous process. Therefore, the need 
arises for related comparison within safety consideration and systematic methodology for 
safety evaluation.  
In the following sessions, the development in continuous pharmaceutical process, the 
previous studies in process screening, selecting and comparing, and concept of inherent 
safety assessment are discussed. The statement of research objective, the description of 
methodology and results of case studies are illuminated as well. 
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2. LITERATURE REVIEW 
 
2.1.  CONTINUOUS PHARMACEUTICAL PROCESS 
Continuous process and batch process are two types of production mode in chemical 
industry in a broad sense. In a batch process, the raw material is charged before the 
processing and the product is discharged after this period of processing. In a continuous 
process, the raw material and the product is charged and discharged simultaneously during 
the period of processing. These definitions can describe either a single unit operation or a 
integrated manufacturing process.  
Compared to the batch process that is widely applied in pharmaceutical industry, 
continuous process is a more efficient production mode of marked advantages (Gutmann, 
Cantillo, & Kappe, 2015).  
Firstly, continuous unit or process is usually less spacious than batch unit or process. 
Take batch vs. continuous reactor as an example, by using continuous manufacturing 
technology, the volume of reactor decreases from at least two cubic meters to at most three 
liters (Hessel et al., 2012). For some industrial chemical production, the volume ratio of 
batch reactor to continuous reactor can be several thousands (Wakami & Yoshida, 2005). 
Significant miniaturization in dimension leads to high efficiency in mass and heat transfer: 
smaller volume means lager heat exchange surface, shorter residence time and much easier 
control of process. This kind of intensification in continuous unit operation further 
provides benefits for integrative production: by reducing footprint of equipment, 
decreasing time between batches and cutting down manual operations between 
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discontinuous steps within one batch, the factory could be designed and manipulated in a 
more compact and efficient way. 
Secondly, the continuous process allows the use of extreme process conditions which 
improve yield. In contrast, these conditions are difficult to achieve in the batch process. 
Most of conventional batch reactors in pharmaceutical facilities do not allow reaction 
temperature above 200 °C and pressure above 10 bar (Damm, Glasnov, & Kappe, 2009). 
These limitations impose restrictions on application of more efficient reactions conditions 
and potential but hazardous synthesis routes. Continuous process, on the other hand, 
enables reaction under more hazardous conditions (300 °C/30 bar) (Damm et al., 2009). 
This growth in tolerance of high temperature and high pressure considerably intensify the 
reaction kinetics and therefore increase the yield. Moreover, the application of extreme 
conditions also provides another approach to speed up the production, that is, the use of 
supercritical solvents. Some substances have enhanced solubility at the temperature and 
pressure above its critical point. For example, supercritical carbon dioxide (scCO2) is one 
of the most frequently used supercritical solvents in the flow chemistry domain. 
Application of scCO2 is actualized in reactions such as condensation, hydroformylation 
and hydrogenation (Gutmann et al., 2015). Compared to traditional organic solvent, scCO2 
is obviously a much safer and eco-friendlier choice for pharmaceutical industry which 
expends a lot of solvent in organic synthesis. 
Thirdly, scaling up for a continuous process is easier, faster and more flexible than 
for a batch process. Pharmaceutical manufacturing has a significant long life cycle 
compared to bulk chemical industry. Demand for drug starts from milligrams in discovery 
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stage and increases to tens of grams even kilogram in the following clinical studies. Once 
the active pharmaceutical ingredient (API) is permitted for commercialized production, 
production amount at the scale of hundreds of tons needs to be guaranteed. For batch 
process, due to its unstable performances in different production scales, significant 
changes are inevitable in scaling up procedure. Some of processes even cannot be scaled 
up owing to technical limitations. In contrast, referring to the literature, continuous process 
in laboratory can be scaled up with less re-optimizations and less changes in synthesis 
route (Gutmann et al., 2015).  
 
2.2.  PROCESS COMPARISON AND SELECTION  
To decide whether to head to novel continuous process or not, evaluations of batch 
and continuous process are in demand for pharmaceutical companies.  
In preliminary stage of the evaluation, fundamental information about reaction 
kinetics, heat transmission and mass transfer is collected and analyzed. The objective of 
this investigation is looking into the technical feasibility of chosen reaction. After these 
basic assessments for intrinsic properties of reaction, far-reaching analyze in economic, 
environmental and safety aspect can be achieved. In this more comprehensive comparison 
based on overall picture, more factors such as expenditure, wastewater treatment and loss 
control measure should be covered. Among these factors, which factor should be selected 
as criterion, how these factors interact, and what’s the correlation between these factors 
and comparison results are questions require to be answered. 
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To answer these questions, some researchers put efforts in individual comparisons of 
manufacturing for specific active pharmaceutical ingredient (API). Most of these studies 
focus on economic advantage of continuous process. Spencer D. Schaber et al.(Schaber et 
al., 2011) estimated the capital, operating and the overall cost for production of a given 
API from synthesis to tablet formulation by integrated continuous and batch 
pharmaceutical manufacturing respectively. Based upon the equal annual yield, the result 
shows that the capital expenditures for continuous production could be markedly lower 
than those of batch mode. Differences in operating and overall cost are not such significant 
but potential saving by material handling and labor in continuous process is explicitly 
illustrated in the study. Hessel, V. et al. compared continuous vs. batch pharmaceutical 
manufacturing for production of ibuprofen and artemisinin on the standpoint of cost and 
environmental impact. Capital expenditure and operating expenditure savings are up to 
57.0% and 51.6% respectively for ibuprofen, while capital expenditure and operating 
expenditure savings are up to 19.6% and 29.3% respectively for artemisinin (Hessel et al., 
2012; Jolliffe & Gerogiorgis, 2016). These study shows the potential economic benefits 
in application of continuous pharmaceutical processes. 
In addition to process comparison, some researchers developed general criterions or 
created systematic methodologies for process selection. Dominique M. Roberge et al. 
(Roberge et al., 2005) classified reactions used in the fine and pharmaceutical industry 
into 4 categories according to kinetic properties. Based on this classification, the very fast 
reactions (reactions time less than 1s) and the fast reactions (reactions occurring from 1s 
to10min) would benefit the most from continuous process. These two types of reactions 
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occupy 44% of all reactions investigated. Ryan L. Harman and Jonathan P. McMullen 
(Hartman, McMullen, & Jensen, 2011) developed a decision roadmap of flow process for 
use in lab-scale. Considering objectives of the study, the intrinsic properties of the 
chemistry and requirements for mixing, heat transferring, related questions are asked at 
the various nodes in this flow map to get the final choice. Gary S. Calabrese and Sergio 
Pissavini (Calabrese & Pissavini, 2011) established an conceptual methodology to 
evaluate applicability of continuous reactor in the form of reaction properties test. They 
measured applicability of flow reactor via series of questions. These questions covered 
issues in reaction properties and some requirements on process. Three “zones” that tagged 
with different level of applicability are defined. Different questions are included for each 
“zone”. For any given reaction, the more answers with “yes” in the “zone”, the higher 
possibility of this reaction to be at the level of applicability that the “zone” stands for. 
 
2.3.  INHERENT SAFETY AND SAFETY ASSESSMENT 
Inherent safety is a well-known concept that has a history of more than 100 years. 
This concept is further developed and carried forward by Trevor Kletz, a famous British 
chemical engineer. He introduced this idea in a 1978 article entitled “What you don’t have 
can’t leak” (Kletz, 1978). In contrast to traditional safety study such as incident prevention 
and mitigation measures, inherent safety emphasizes eliminations of intrinsic hazards in 
the process, rather than protective activities. There are four main principles to achieve 
application of inherent safety proposed by Kletz (Kletz, 1991): 
 Minimization: decreasing the amount of hazardous materials  
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 Substitution: Replacing hazardous materials with less hazardous substitutes 
 Moderation: Operating the process at less harsh conditions (using dilute reaction, 
applying low pressure, low temperature, etc.) 
 Simplification: Eliminating problems by designing instead of adding protective 
equipment to deal with them  
Compared to conventional approach to control hazard by the protective system, 
inherent safety approach is usually hard to apply in the early stage of process design, 
however, once this concept is integrated in process design, intrinsic vulnerability of 
process could be reduced significantly.  
To quantify level of inherent safety in manufacturing facility, many researchers 
proposed different methodologies for inherent safety assessments. Numerous assessments 
proposed recently are in the form of indices. Most of indices divide hazards into two types, 
chemical hazards and process hazards, then discuss specific parameters that influence each 
kind of hazard separately, and integrate chemical and process factors to get the final result.  
According to literature, the first safety index is Dow’s Fire & Explosion Index 
developed by Dow Chemical Company in 1964. Dow’s Fire & Explosion Index (F&EI) 
is a widely used quantification of inherent safety and is one of the leading hazard index 
recognized by the chemical industry. Another useful tool developed by Dow Company is 
Dow’s Chemical & Exposure Index (C&EI) which considers toxic exposure and is used 
in conjunction with Dow’s F&EI (AIChE, 1994). 
The first published index that totally surrounded inherent safety was “quantifying 
inherent safety of chemical process routes” by Lawrence in 1996(Lawrence, 1996). Based 
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on Lawrence’s work, another index for inherent safety assessment was proposed by 
Heikkila in 1999 named “inherent safety index” (Heikkilä, 1999). This index introduced 
the fundamental concept to rank the chemical process on the basis of temperature, pressure, 
composition in the unit, etc. It is a more specific index that aims at inherent safer design 
and becomes the prototype for the following development in this field. Besides of this 
conventional safety indices, there is another type of modified approach of index towards 
inherent safety, that is the Fuzzy Logic Based Inherent Safety Index developed by Gentile 
(Gentile, Rogers, & Mannan, 2003). Fuzzy logic accounts for uncertainties in the 
quantitative hazard and risk assessment. By transform hierarchical ranking into fuzzy 
ranking, this index successfully combines quantitative modeling and qualitative expert 
judging.  
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3. PROBLEM STATEMENT 
 
Although advantages of continuous process in pharmaceutical manufacturing are 
illustrated by many studies, it is still too early to claim that continuous process is the right 
direction to go forward. Several gaps in the literature survey are required to be focused on.   
Firstly, most of process selection methodologies are confined to analyzing separate 
properties of reaction taken in process, rather than evaluation in a systematic way. For 
example, small inventory is usually identified as one of significant advantage of 
continuous process, however, it is possible that to achieve similar yield in the 
corresponding batch process, the reaction in continuous process requires more intensified 
conditions like higher temperature, higher pressure, and higher concentration of hazardous 
chemicals. Selection and comparison by independent and individual parameters without 
integration is not enough.  
Secondly, existing comparisons between batch and continuous processes mainly 
focus on economic aspect, while lacking combination of safety issue and other important 
aspects from real production. Although the driving force for the application of this novel 
process is the economic interests, safety issues directly determine its feasibility. A choice 
between batch and continuous process needs to be made based on business performance 
within acceptable safety levels. Those comparisons that merely consider the profits are not 
enough. 
Thirdly, the existing studies are limited to fixed production system. Potential 
problems in a different scale are not considered. In the pharmaceutical industry, gradually 
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increasing production scales is required which is different from the bulk chemical industry. 
Hence, safety of process conditions needs to be guaranteed for all scale production. 
Comparison only based on fixed scale is not comprehensive. 
Therefore, the primary objective of this study is to provide a comprehensive and 
systematic comparison between batch and continuous process used in pharmaceutical 
industry. Then on the basis of this analysis, this study will evaluate how main factors 
considered in Dow F&EI impact the safety level for these two different processes. Finally, 
this study will provide support to further improve existing methodology for process 
screening and selection for pharmaceutical industry. 
It is worth mentioning that there are other risks such as chemical exposure for 
pharmaceutical manufacturing, however, this study mainly focuses on potential fire, 
explosion and reactivity incident. In addition, comparison in this study focuses on intrinsic 
properties of the reaction and process which are the major hazards of the reaction system. 
Therefore, other factors like loss control measures and emergency equipment are supposed 
to be effective for both batch and continuous systems. 
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4. METHODOLOGY 
 
4.1.  INTRODUCTION 
To measure the realistic fire, explosion and reactivity potential of batch and 
continuous process, Dow’s Fire and Explosion Index (F&EI) methodology is applied as 
hazard index in this study, since it is the most widely used hazard index that recognized 
by the chemical industry (AIChE, 1994).  
From the first edition of Dow’s Fire & Explosion Index Hazard Classification Guide 
in 1964, this index has been continuously improving though the past 50 years. The last 
version is the seventh edition that published in 1994. The purposes of this index include 
forecasting quantitative damage of potential explosion, reactivity incidents and fire; 
determining hazardous equipment which is possible to give rise to incidents in the system; 
conveying this F&EI risk potential to related managements and organizations. Since the 
aim of this study is to identify major hazard that affect selection, application of Dow F&EI 
will be mainly focus on its function of hazard identification. 
 
4.2.  PROCEDURE FOR HAZARD IDENTIFICATION 
Procedure for calculating Dow F&EI is shown in the Figure 1.  
The first step, selection of pertinent process unit is usually made considering 
following factors: chemical energy potential, quantity of hazardous material, capital 
density, process operation conditions, malfunctions history and special operations. In 
current study, because the primary difference between continuous and batch systems is 
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operation of reactor, batch and continuous reactors are defined as research unit in the 
following calculation. 
 
 
Figure 1. Procedure to Calculate Fire & Explosion Index 
(AIChE, 1994) 
 
The second step is calculation of Material Factor (MF). MF is a measure of inherent 
potential of energy releasing from fire or explosion due to combustion or chemical 
reaction. Value of this factor can be obtained from NFPA 325M, NFPA 49, material safety 
data sheet or calculated manually based on flammability and instability of substances 
involved.  
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The third step is determination of the Process Unit Hazard Factor (F3). In Dow’s 
F&EI, the value of the Process Unit Hazard Factor is constituted of the General Process 
Hazard Factor (F1) and the Special Process Hazard Factor (F2): 
The general process hazard factor (F1) considers hazards that take primary roles when 
evaluating the level of loss in incident. It involves with hazards that are applicable for 
most of process situation, such as impact of exothermic/endothermic reaction, material 
handling and transfer, maintenance construction and issues related to emergency 
equipment. In contrast, the special process hazard factor (F2) represents specific process 
conditions that exhibited to be primary causes for incidents. Influences of elements like 
toxicity, operating pressure, flammable conditions, dust explosion, corrosion, leakage and 
use of special equipment are assessed in the calculation.  
The Process Unit Hazard Factor (F3) is product of the General Process Hazard Factor 
(F1) and the Special Process Hazard Factor (F2). The final result of F&EI is calculated by 
following formula: 
F&EI = MF×F3 
Higher the value of F&EI, larger the magnitude of estimated damage once incident 
happens. Ranking values of F&EI to measure degree of hazard are given in the Table 1. 
In addition to F&EI, the Process Unit Hazard and the Material Factor Hazard can indicate 
severity of secondary events independently.  
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Table 1. List of Degree of Hazard for F&EI (AIChE, 1994) 
Degree of Hazard for F&EI 
F&EI Index Range Degree of Hazard 
1-60 Light 
61-96 Moderate 
97-127 Intermediate 
128-158 Heavy 
159-up Severe 
 
4.3.  CORRELATION TO ECONOMIC ANALYSIS 
Provided additional information, calculation of Fire & Explosion Index can be used 
for following risk analysis, such as property damage. The flowsheet for risk analysis is 
shown in Figure 2. 
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Figure 2. Risk Analysis Procedure (AIChE, 1994) 
 
Three basic factors, including F&EI, the Loss Control Credit Factor, and the Damage 
Factor, provide support for this risk analysis. F&EI can be transformed to Radius of 
Exposure (R) via multiplying the F&EI factor by a factor of 0.84. Unit of this estimated 
radius is meter. Then, area of exposure is calculated by the equation: Area =  πR2. The 
Loss Control Credit Factors considers all the loss control properties and preventive 
measures that refrain system from severe incidents and play a role in weakening the 
frequency and consequence of specific scenarios. Three types of loss control properties 
are included in calculation: Process Control (C1), Material Isolation (C2) and Fire 
Protection (C3). Base on installation of related device and fulfillment of related regulation, 
penalties is accumulated for factors of each category. The Loss Control Credit Factor is 
the product of these three factors. The damage factor demonstrates the total impact of fire 
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and blast damage due to loss of content in a process unit. Determination of the Damage 
Factor is based on the Process Unit Hazard Factor (F3) and the Material Factor (MF).  
Once F&EI, the Loss Control Credit Factor and the Damage Factor are confirmed, 
provided information about expenditure on equipment, following economic loss risk 
analysis can be done. The Base Maximum Probable Property Damage (Base MPPD) is the 
product of Value of Area of Exposure and Damage Factor. This parameter represents 
economic loss without control feature to mitigate this loss. The Actual Maximum Probable 
Property Damage (Actual MPPD) is determined by multiplying Base MPPD and the Loss 
Control Credit Factor. The Actual MPPD represents the economic loss while adequate 
protective measures functioning in the incident. Another important parameter is the 
Maximum Probable Days Outage (MPDO) which is a significant factor in evaluating the 
potential Business Interruption (BI). Usually, the indirect economic loss in BI frequently 
equal even exceed that of property damage that directly resulted from the incident. The 
MPDO value is correlated with the Actual MPPD value. BI is calculated by the formula 
below: 
BI =  
MPDO
30
×VPM × 0.70 
In this formula, VPM represents the Value of Production for the Month, and 0.70 
represents the sum of fixed costs and profits.  
From description of procedure aforementioned in the Dow’s Fire & Explosion Index 
Hazard Classification Guide, economic analysis is confined to financial loss after an 
incident. Correlation between safety and economic gain from production is not built. 
Actually, this kind of connection could be established via yield of reactions and geometry 
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and inventory of units, since these factors take important role in both safety assessment 
and process gain. In the current study, this correlation between safety and profit is 
constructed on the foundation of Dow’s Fire & Explosion Index.  
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5. CASE STUDY I: BENZIMIDAZOLE SYNTHESIS 
 
5.1.  OVERVIEW 
Benzimidazole derivative is an important type of intermediates in pharmaceutical 
industry. It is widely exhibited in a variety of pharmaceutical substance, such as proton 
pump inhibitors, antimicrobials, antivirals, anticancer, anti-inflammatory, hormone 
modulators as well as depressants, antidiabetics and so on (Bansal & Silakari, 2012). 
Famous drug with benzimidazole nucleus includes Omeprazole and Albendazole. 
Omeprazole is used to treat gastroesophageal reflux disease and peptic ulcer disease 
(AHFS Monographs, 2017), and Albendazole is an effective drug in treatment of 
various parasitic worm infestations(AHFS Monographs, 2017). The molecular structures 
of benzimidazole, Albendazole, and Omeprazole are shown in Figure 3. 
 
a)                                                                 b)                                                     
 
  c) 
 
   
 
Figure 3. a) Molecular Structure of Benzimidazole, b) Molecular Structure of 
Albendazole, c) Molecular Structure of Omeprazole  
(reprinted from Bansal & Silakari, 2012) 
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2-methyl benzimidazole is a pharmaceutical-potential substance that belongs to this 
benzomidazole ring system. As presented in Figure 4, the condensation of o-
phenylenediamines with carboxylic acids is one of the most common synthesis route for 
2-methyl benzimidazole (Patil, Ganguly, & Surana, 2008). Conditions and production 
comparisons of o-phenylenediamines condensation by batch vs. continuous processes are 
showed in Table 2 (Damm et al., 2009). These fundamental parameters are used for safety 
evaluation by Dow’s F&EI in the following study. 
 
 
Figure 4. Synthesis of 2-methyl Benzimidazole by Condensation of o-phenylenediamine 
 
 
Table 2.  Production Conditions of Batch and Continuous Processes 
 for Synthesis of 2-methyl Benzimidazole 
 Batch Process Continuous Process 
Temperature (°C) 200 270 
Pressure (psi) 145 1885 
Reaction Time (min) 5 0.5 
Yield (%) 98 94 
Substrate Concentration (M) 5 1 
Reaction Volume (ml) 1000 4 
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In order to concentrate on study in intrinsic differences between two processes, and 
simplify the hazard identification in F&EI, several assumptions are adopted:  
1. The reaction mass is perfect mixed in reactors; 
2. Adjunct cooling systems in both processes are in perfect performances; 
3. Emergency equipment is same and in perfect performances in both processes; 
4. Scalabilities of both processes are good enough that reaction conditions remain 
same in all scales. 
 
5.2.  SAFETY COMPARISON RESULT 
The comparison is conducted based on material properties and process features. 
Related explanation is stated below. 
 
5.2.1.  COMPARISION OF MATERIAL 
In this study, impacts from intrinsic properties of reactants are same for both 
processes. Material factors of all substances are listed in Table 3. According to Dow’s Fire 
and Explosion Index Hazard Classification Guide, impact from the most hazardous 
material dominates the material factor of the whole process, therefore only impact from 
acetic acid is considered for both processes. In addition, although temperatures and 
composition are different in two processes and may lead to different chemical properties, 
these features are neglected in this part and contained in process comparison.  
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Table 3. Material Factor for Batch and Continuous Reactor 
 Batch Reactor Continuous Reactor 
o-phenylenediamine 10 10 
2-methyl Benzimidazole 1 1 
Acetic Acid 14 14 
 
5.2.2.  COMPARISON OF PROCESS 
First of all, it’s worth mentioning that albeit lots of distinctions exist between batch 
and continuous processes (see Figure 5), comparisons in this study are confined to 
synthesis in reactor on account of its core role in the whole process: operation mode of 
reactor – continuously or intermittently – determines whether the process is continuous or 
not from the start (see Figure 6). Therefore, the reactor is selected as the pertinent process 
unit without conventional unit screening procedure. 
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Figure 5. Procedure for Pharmaceutical Production (Das, 2012) 
 
 
Figure 6. Differences in Structure between Batch and Continuous Reactors 
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On the foundation of safety evaluation by Dow’s Fire & Explosion Index, 
quantitative judges between batch and continuous process are illustrated through 
comparison in sensitivity and productivity within safety consideration.  
 
5.2.2.1.  SENSITIVITY ANALYSIS 
This sensitivity analysis focus on correlation between safety level and inventory of 
reactor. Inventory of unit plays an important role in the safety. In addition, this sensitivity 
analysis can also provide supportive information for scaling up procedure.  
Inventory of unit plays an important part in the safety via quantity of flammable or 
unstable material. This potential is considered in both the General Process Hazards (F1) 
and the Special Process Hazards (F2) according to Dow’s F&EI Hazard Classification 
Guide. In general, more the flammable or unstable material, higher the risk of fire and 
explosion within the process. For different unit (process unit or storage unit) and different 
phase (liquid, gas or solid), different correlation formula between inventory and penalty 
is given in the Special Process Hazards (F2) part of the Dow’s F&EI Guide. Moreover, 
other issues such as whether these materials are processed indoor or outdoor, what’s the 
temperature to handle these materials influences the safety level as well. These questions 
are included in the General Process Hazards (F1) part.  
In this sensitivity analysis, F&EI that combines both the general and the special 
process hazards is expressed as a dependent variable that changes with the variation of 
total inventory of reactor. Other operation conditions remain the same for different 
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inventory. Correlations between the F&EI and material inventory for batch and continuous 
process are shown in the Figure 7. 
 
 
Figure 7. Analysis of Sensitivity to Inventory for Batch and Continuous Reactors 
Based on 2-methyl Benzimidazole Synthesis 
 
Expressions of F&EI as a function of inventory for batch and continuous reactor are 
shown below:  
For batch reactor, 
If 0 lb < Inventory < 20833 lb: 
F&EI = 4×10−9×(Inventory/lb)2-3×10−5×(Inventory/lb)+84.003  
If 20833 lb < Inventory < 30000 lb: 
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F&EI = 3×10−9×(Inventory/lb)2-5×10−5×(Inventory/lb)+95.108 
For continuous reactor, 
If 0 lb < Inventory < 10000 lb: 
F&EI = 1×10−8×(Inventory/lb)2- 4×10−5×(Inventory/lb)+81.507 
If 10000 lb < Inventory < 30000 lb: 
F&EI = 4×10−9×(Inventory/lb)2- 3×10−4×(Inventory/lb)+90.98 
These formulas are generated by Microsoft Excel using the 2nd polynomial trend line. 
R-square values for these formulas are all greater than 0.99.  
for 0 lb < Inventory < 10000 lb: 
F&EI of batch reactor is slightly greater than continuous reactor. This difference 
mainly comes from difference in usage of stirrer and reaction pressure. Due to requirement 
for homogeneous mixture, stirrer is necessary in batch reactor, while such a stirrer is not 
needed (or not allowed) in a continuous tubular reactor. Thus, stirrer, as a hazardous 
rotating equipment, adds extra penalty to batch process. As for difference in pressure, 
higher penalty is given to continuous process for its intensified condition. From the result, 
influence from rotating equipment is greater than that from pressure in this case.  
Another observation is that, the magnitude of the difference in the F&EI between two 
reactors decreases with the growing inventory. This trend stems from the increasing 
impact from quantity of hazardous material. When inventory approaches zero, difference 
in F&EI is mainly caused by stirrer and distinct pressure aforementioned. As inventory 
increases, influence from unstable material extends. This influence depends on 
composition of mixture, or more specifically, concentration of acetic acid that defines the 
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Material Factor (MF). Based on information of reactions, molar concentrations of acetic 
acid in batch and continuous reactor are 8.31M and 15.66M respectively. Thus, for similar 
total inventory, penalty from hazardous material in continuous reactor is greater than batch 
reactor.  
when 10000 lb < Inventory < 20833 lb: 
F&EI of continuous reactor is signally higher than batch reactor, and this difference 
grows along with the increasing inventory. In this range, part of influences come from 
rotating equipment, pressure and increasing inventory that mentioned above. More 
importantly, quantity of flammable and unstable liquids handled above boiling point 
exceeds threshold of 10,000lb for continuous reactor, therefore give a vertical rise to F&EI 
for continuous reactor, as shown in the Figure 7. This threshold is illustrated clearly in 
Dow’s F&EI Hazard Classification Guide: when quantity of flammable and unstable 
liquids above its boiling point is less than 10,000 lb, a penalty of 0.60 is determined. A 
penalty of 0.90 is given when this liquids quantity above its boiling point is greater than 
10,000 lb. In this case study, operation temperature of continuous reactor (270°C) is higher 
than boiling point of both o-phenylenediamine (257°C) and acetic acid (118°C), while 
operation temperature of batch reactor (200°C) merely higher than boiling point of acetic 
acid (118°C). Therefore, for inventory in the range of 10,000lb to 20833lb, total mass in 
continuous reactor is defined as unsafe, while merely acetic acid mass is defined as unsafe 
in the batch reactor. This divergence leads to different penalty in this range of inventory. 
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when 20833 lb < Inventory < 30000 lb: 
F&EI of batch reactor drastically increases. However, F&EI of continuous reactor is 
still slightly greater than batch reactor, and the magnitude of this difference increases with 
the growing inventory.  
This vertical rise in the F&EI of batch reactor is also caused by critical quantity of 
material above the boiling point. When total quantity in batch reactor goes beyond 
20,833lb, quantity of flammable and unstable substance - acetic acid - also goes beyond 
threshold of 10,000 lb. Thus, penalty from material above boiling point is similar for both 
of processes.  
The higher F&EI of continuous reactor originated from quantity of flammable and 
unstable material in this range of inventory. Since higher concentration of acetic acid is 
applied in continuous reactor, more proportion of substance is identified as unsafe for 
continuous reactor, thus higher penalty is given. This explanation is similar to that in range 
of low inventory (< 10,000 lb). However, unlike appearance in the low inventory range, 
influence from these flammable and unstable materials exceeds impact from pressure and 
stirrer. Therefore, continuous reactor becomes more dangerous for this range of total 
inventory. 
It’s worth mentioning that higher inventory is not considered here. Upper limit of 
inventory (30,000 lb) is set based on the general highest inventory of reactor used in 
pharmaceutical manufacturing. 
Degree of hazard for batch versus continuous reactor used in this case study is shown 
in Table 4. In the range of inventory investigated, batch reactor is identified as moderate 
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hazardous for a broader range of inventory, while continuous reactor is identified as 
intermediate hazardous for a broader range of inventory. Even so, It’s worth mentioning 
that the F&EI values for both reactors are in a relative safe range (F&EI > 128 indicates 
heavy even severe hazard). 
 
Table 4. Degree of Hazard for Batch and Continuous Reactors 
Material Inventory X Batch Reactor Continuous Reactor 
X < 15,152 lb Moderate Moderate 
15,152 lb < X < 20,833 lb Moderate Intermediate 
20,833 lb < X < 30,000 lb  Intermediate Intermediate 
 
 
 
In summary, F&EI for both batch and continuous reactors increase as material 
inventory increases. Moreover, F&EI of continuous reactor is more sensitive to change of 
inventory comparing to batch reactor. This higher sensitivity caused by comprehensive 
influence from higher concentration of unstable and flammable material, higher operation 
temperature and higher pressure it applied. 
 
5.2.2.2.  SAFETY VS. PRODUCTIVITY EVALUATION 
Evaluation in this part mainly focuses on safety of batch versus continuous process 
base on productivity considerations. Emphasis on productivity scale of this study primary 
comes from flexibility required for pharmaceutical production. Pharmaceutical industry is 
highly supply driven. Requirement on production rate is changed according to demand of 
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market all the time. Therefore, better understanding on correlation between safety and 
productivity provides practicable support for research in process selection. 
To approach this target, safety level is evaluated for the process at the same 
productivity capacity, as shown is Figure 8. In this part, F&EI is regarded as indicator for 
safety evaluation as above. Annual production is set as indicator for productivity. Related 
formula is shown below. 
 
Figure 8.  Basic Idea for Safety Comparison Based on Productivity 
 
General calculations for productivity capacity are: 
Annual Production = Product Yield ×Annual Operation Time 
Product Yield = Mass Flow of Reagent ×Conversion 
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Mass flow is supposed to be proportional to reactor volume as set in the laboratory 
trial.  
According to definition of fine chemical, annual production of fine chemical is 
limited to 1,000 tons per year (Patt et al., 2002). Therefore, 1,000 tons per year is set as 
the upper limit in this evaluation.  
As for product yield and annual operation time, the former is provided in Table 3, 
and expression for the latter is formed referring to the normal operation time (Latexman, 
2013). 
Annual operation time for batch reactor is: 
Annual Operaton Time = 300 day/yr ×24 hr/day 
Annual operation time for continuous reactor is: 
Annual Operation Time = 8000 hr/yr 
Normally, in pharmaceutical industry, multi products are produced in one production 
line. Therefore, the same product cannot occupy the producing line for the whole year. In 
this study, 2-methyl benzimidazole is assumed to be produced in 2 months of one year. 
In addition, circulating time in batch reactor need to be considered. According to the 
literature (Damm et al., 2009), the ratio of reaction time to total operation time for this 
reaction is shown below. Excepted reaction, other operations include filling, cleaning and 
cooling and other additional work. 
Reaction Time
Total Operation Time
= 0.185 
Based on these formulas and assumptions, correlation between annual productions 
and F&EI is shown in the Figure 9. 
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Figure 9.  Analysis of Safety Based on Production for Batch and Continuous  
Reactors Based on 2-methyl Benzimidazole Synthesis 
 
According to the Figure 9, F&EI value is constant in the range of practicable annual 
production (0 ~ 1000 tons per year). Plus, the F&EI for both reactors corresponds to a 
moderate level of hazard (61 < F&EI < 96).  
This low F&EI resulted from relatively low demand for production. According to the 
sensitivity analysis, F&EI for both batch and continuous reactor increase as material 
inventory increases. Both processes could be intermediate hazardous once its inventory is 
higher than a specific value. However, these values are unapproachable in practical 
pharmaceutical manufacturing. Since demand for fine chemical, always less than 1,000 
tons per year, confines scale of production.  
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Another observation is that, the F&EI of continuous reactor is always lower than that 
of batch reactor for same production. Plus, slight rise appears for batch reactor when 
production capacity exceeds 500 tons per year. These appearances predicate consistent 
superiority in safety for continuous reactor than batch reactor. Explanation is stated below:  
Firstly, as stated in the sensitivity analysis, settled elements, such as operation 
pressure, temperature and use of rotating equipment, take major account for the difference 
at small-scale production. Advantages of continuous process in these aspects determine 
its superiority in small-scale pharmaceutical production. 
Secondly, continuous reactor possesses higher space-time yield compared to batch 
reactor. This advantage stems from the intrinsic property of continuous operation mode - 
the low residence time and high flow throughput. That is to say, it costs fewer time and 
lower inventory for continuous reactor to produce same amount of product than batch 
reactor. These benefits in production efficiency influence safety level indirectly but 
significantly: Smaller inventory means fewer unstable materials in process, and shorter 
operation time means less chance to fail. This point is not considered in separate safety 
evaluation, but can be clearly illustrated by correlation between production capacity and 
F&EI. In this case, when demand on production growing, demand on inventory grows 
faster for batch reactor than continuous reactor. This faster rise in inventory lead to faster 
rise in amount of unstable material in process so as to the faster rise in F&EI value. It 
explains why slight rise appears for batch reactor when production capacity exceeds 500 
tons per year. 
 34 
 
In fact, the comparable batch and continuous reactor are rarely at the same level of 
volume. Referring to literature, for commercial production of fine chemical, the volumes 
of continuous reactor are usually in a range of 0.1 to 3 liter, while the volume of batch 
reactor is usually around the range of 2 to 10 cubic meters (Hessel et al., 2012). For this 
case, based on assumption of same annual production, as presented in Figure 10, the ratio 
of batch reactor inventory and continuous reactor inventory is as much as one hundred. 
 
Figure 10. Comparison in Reactor Volume between Batch and Continuous 
Process for Equal Amount in Production 
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6. CASE STUDY II: OXIDATION WITH HYDROGEN PEROXIDE 
 
6.1.  OVERVIEW 
Hydrogen peroxide is one kind of widely used oxidation agent in pharmaceutical 
production. Typical reaction involving hydrogen peroxide includes Baeyer–Villiger 
oxidations for synthesis of lactone (Gutmann et al., 2015), N-oxidation of alkyl pyridine 
for synthesis of alkyl pyridine N-oxidant (Pineda-Solano et al., 2012) and benzylic 
hydro-peroxide rearrangement for synthesis of Brivanib alaninate (LaPorte et al., 2014).  
This common oxidation agent is also used in production of peracetic acid. As shown 
in Figure 11, peracetic acid is produced via oxidation of acetic acid by hydrogen peroxide 
with sulfuric acid as the catalyst. Conditions for peracetic acid production by batch vs. 
continuous process are showed in Table 5 (Fatemeh Ebrahimi, Kolehmainen, & Turunen, 
2009).  
 
 
Figure 11. Synthesis of Peracetic Acid by Oxidation of Acetic Acid 
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Table 5.  Production Conditions of Batch and Continuous Process 
for Synthesis of Peracetic Acid 
 Batch Process Continuous Process 
Temperature (°C) 60 80 
Pressure (psi) 14.5 14.5 
Reaction Time (min) 30 15 
Yield (kg/h) 170 20 
Acetic Acid Concentration (M) 7.3 7.3 
Reaction Volume (L) 4000 10 
 
Assumption for this case study is listed below: 
1. The reaction mass is perfect mixed in reactors.  
2. Since the temperature for decomposition of hydrogen peroxide in peracetic acid 
synthesis reaction is higher than 120 °C (Kadla & Chang, 2001), which is larger 
than operation temperature for both processes in the case study, decomposition of 
hydrogen peroxide is assumed to be inexistent. 
3. Sulfuric acid is dissociated completely to H+ and HSO4
–
, in addition, concentration 
of H+ is assumed to be constant of 0.67 mol/L during the reactions for both 
processes. 
4. Influence from sulfuric acid is not considered in safety evaluation. 
5. Emergency equipment and cooling system are perfectly performed for both of 
processes. 
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6. Scalabilities of both processes are good enough that reaction conditions remain 
same in all scales. 
 
6.2.  SAFETY COMPARISON RESULT 
The comparison is conducted based on material property and process feature. 
Related explanations are stated in the following paragraph.  
 
6.2.1.  COMPARISON OF MATERIAL 
In this case, impact from material within the reactor is same for both of processes. 
Material factors for reactants involved are listed in Table 6. According to Dow’s Fire and 
Explosion Index Hazard Classification Guide, influence from the most hazardous material 
dominates the material factor. Although material factor values are same for hydrogen 
peroxide and peracetic acid, since concentration of hydrogen peroxide is higher than 
peracetic acid, hydrogen peroxide is chosen to be the dominant material. Therefore, only 
impact from hydrogen peroxide is considered for both processes. Change on substances’ 
property from temperatures are neglected in this part and reconsidered in process 
comparison.  
Table 6. Material Factor for Batch and Continuous Reactor 
 Batch Reactor Continuous Reactor 
Acetic Acid 14 14 
Hydrogen Peroxide 24 24 
Peracetic Acid 24 24 
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6.2.2.  COMPARISON OF PROCESS  
The major difference between these two production processes come from distinctions 
in reaction conditions and reactor constructions. These differences are shown in Table 5 
and Figure 6. Based on safety evaluation by Dow’s Fire & Explosion Index, quantitative 
judges between batch and continuous process are illustrated through comparison in 
sensitivity and productivity within safety consideration.  
 
6.2.2.1. SENSITIVITY ANALYSIS 
Procedure for sensitivity comparison is the same as the first case study. Correlations 
between the F&EI and material inventory for batch and continuous process are shown in 
the Figure 12. 
 
 
Figure 12. Analysis of Sensitivity to Inventory for Batch and Continuous Reactors 
 Based on Peracetic Acid Synthesis 
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Expressions of F&EI as a function of inventory for batch and continuous reactor are 
shown below:  
For batch reactor, 
If 0 lb < Inventory < 11000 lb: 
F&EI = 4×10−10×(Inventory/lb)2 − 2×10−6×(Inventory/lb)+130.85  
If 11000 lb < Inventory < 30000 lb: 
F&EI = 2×10−9×(Inventory/lb)2 −  4×10−5×(Inventory/lb)+141.95 
For continuous reactor, 
If 0 lb < Inventory < 11430 lb: 
F&EI = 2×10−9×(Inventory/lb)2 − 1×10−5×(Inventory/lb)+ 109.25 
If 11430 lb < Inventory < 30000 lb: 
F&EI = 4×10−9×(Inventory/lb)2 −  4×10−5×(Inventory/lb)+118.35 
These formulas are generated by Microsoft Excel using the 2nd polynomial trend line. 
R-square value for these formulas are all greater than 0.99.  
for 0 lb < Inventory < 11000 lb: 
F&EI of batch reactor is larger than continuous reactor. This difference is almost 
caused by usage of stirrer in batch reactor. Application of such a rotating equipment 
increases penalty for batch process.  
when 11000 lb < Inventory < 11430 lb: 
F&EI of batch reactor is still higher than continuous reactor, but this difference grows 
drastically due to the sharp transition in F&EI of batch reactor. This transitions is caused 
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by quantity of flammable liquids that handled above flashing point exceeds threshold of 
10,000lb. This threshold is illustrated clearly in Dow’s F&EI Hazard Classification Guide: 
when quantity of flammable liquids above their flashing point is less than 10,000 lb, a 
penalty of 0.30 is determined. A penalty of 0.45 will be given when this quantity of 
flammable liquids above their flashing point is larger than 10,000 lb. For peracetic acid 
production, operation temperature for batch reactor (60°C) and continuous reactor (80°C) 
is higher than flashing point of both acetic acid (39°C) and peracetic acid(40.5°C). 
Therefore, the value of inventory for higher penalty is determined by compositions of 
peracetic acid and acetic acid in reactors. Since concentrations of these two materials is 
slightly higher for batch comparing to continuous reactor, batch reactor approaches this 
transition in F&EI at a smaller total inventory. 
when 11430 lb < Inventory < 30000 lb: 
F&EI of continuous reactor exceed the transition caused by quantity of unsafe 
material above flashing point. However, it is still lower than F&EI of batch reactor.  
Compared to the first case study, value of slope for both processes is similar low. It 
results in the consistent superiority of continuous reactor in safety level compared to batch 
reactor. This similarity in slopes comes from similarity in operation conditions. 
Differences only appear in operation temperature and hydrogen peroxide concentration. 
These differences are not such significant that lead to huge divergence between slopes. 
Thus, difference in F&EI value between two reactors does not change along with 
increasing inventory.  
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Degree of hazard of this case study is exhibited in Table 7. Although marked 
transitions appears for both reactor, safety levels for two reactors do not change based on 
scaling up of reactor size. The safety levels are majorly decided by settled parameters, 
such as operation pressure and usage of stirrer. These parameters do not change with 
inventory as variable. Hence, inventory does not play a significant role in judgement on 
degree of hazard.  
 
Table 7. Degree of Hazard for Batch and Continuous Reactors 
Reactor Type Batch Reactor Continuous Reactor 
Degree of Hazard Heavy Intermediate 
 
In sum, F&EI for both batch and continuous reactor increase as material inventory 
increases due to the increases of quantity above flashing point. However, since operation 
conditions are relatively mild and similar for these two reactors, both reactor do not exhibit 
high sensitivity when inventory is growing gradually. 
 
6.2.2.2.  SAFETY VS. PRODUCTIVITY EVALUATION 
For evaluation based upon productivity, assumption for practical production are set 
as following: 
1. Confined by the conversion of this reaction route and volume of reactor, upper  
limit for annual production is settled to be 580 tons per year. 
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2. Same as the first case study, referring to normal operation time for this two operation 
mode(Latexman, 2013), annual operation time for batch reactor is 8760 hour per day, 
and annual operation time for continuous reactor is 8000 hour per day.  
3. Peracetic acid is assumed to be produced for 2 months in one year. 
4. According to the literature (Ebrahimi et al., 2009, Ebrahimi et al., 2011), the ratio of 
reaction time to total operation time for this reaction is : 
Reaction Time
Total Operation Time
= 0.143 
Based upon these formulas and assumptions, correlation between annual productions 
and F&EI is shown in the Figure 13. 
 
 
Figure 13.  Analysis of Safety Based on Production for Batch and Continuous Reactors 
  Based on Peracetic Acid Synthesis 
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According to the Figure 13, F&EI is stabilized at 109 in the range of practicable 
annual production for continuous reactor. For batch reactor, the F&EI value rise drastically 
when the annual production is higher than 220 tons per year. 
For the batch production mode, relatively low production efficiency leads to 
substantial increase in reactor volume when demand on production grows. This increase 
in reactor volume is so significant that exceed the threshold for large quantity of 
flammable and unstable material above flashing point. Therefore, the F&EI value jump 
from 131 to 143 when the annual production is higher than 220 tons per year. 
For continuous production mode, high production efficiency causes only a few 
change in volume hence only few change in F&EI in as well. This difference in F&EI 
between batch and continuous reactor means that, to produce the same amount of peracetic 
acid in the given period, the volume of continuous reactor is much smaller than batch 
reactor.  
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7. RESULT SUMMARY 
 
Figure 14 represents the comparisons of two case studies. The X-axis represents two 
different case studies, and the Y-axis represents the average Dow’s F&EI value which can 
be used to define the degree of hazard. 
 
 
Figure 14.  Comparison of Safety Level by Batch and Continuous 
Productions for Two Case Studies 
 
Regardless of the reactor type, the safety level is predetermined by properties of the 
synthesis reaction. Although distinctions in F&EI appear when using different reactors for 
both cases, peracetic acid production is generally more hazardous than 2-methyl 
benzimidazole production, no matter which reactor it uses. This higher level of danger 
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comes from the intrinsic properties, which consist of the flammability and reactivity of the 
chemicals involved in the synthesis of peracetic acid.  
Taking batch and continuous reactors into consideration, distinction in F&EI comes 
from the differences in operation conditions and production efficiency.  These varying 
factors such as temperature, pressure, and yield do not influence F&EI as individual 
factors. Instead, they are correlated and impact the F&EI as an ensemble. Difference in 
these ensembles decides the variance in F&EI value between reactors, then determines to 
which extent the selection of reactor can make a difference. For this study, the variance in 
F&EI value between batch and continuous reactor is greater for peracetic acid production 
(variance in F&EI = 28) than 2-methyl benzimidazole production (variance in F&EI = 
2.6). Therefore, selecting a reactor is more important for peracetic acid comparing to 2-
methyl benzimidazole production.  
The importance of choosing a reactor is different for the two cases, the F&EI value 
for a continuous reactor is lower than a batch reactor for both cases. This consistency 
exhibits the superiority of a continuous reactor in safety.  
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8. CONCLUSION 
 
A comprehensive comparison between the batch and continuous process used in the 
pharmaceutical industry based upon Dow’s F&EI is made in this study. Two typical 
pharmaceutical productions, the production of 2-methyl benzimidazole and the production 
of peracetic acid are analyzed. Safety levels for batch and continuous reactors are 
compared based on both inventory and annual production being used as variables. The 
conclusions on the foundation of these two case studies are stated below:  
1. The comparison of batch versus continuous processes in the pharmaceutical industry 
is complex. It’s determined by reaction properties, operation conditions, structures of 
equipment, production efficiency, scale of production, and many other factors. To get 
a conclusive comparison between these two production modes, more systematic 
studies based on the integrated batch and continuous process need to be conducted for 
safety consideration. 
2. Just focusing on the reactor in which part of API synthesis occurs, the continuous 
reactor is more sensitive to inventory in general. The magnitude of this sensitivity is 
determined by operation conditions such as operation temperature, operation pressure 
and concentration of hazardous material. This sensitivity to inventory might lead to 
problems for continuous production in a relatively large scale. 
3. However, when considering practical pharmaceutical production, which is always in 
a small scale (no larger than 1000 tons per year), hazardous large-volume continuous 
reactor is not necessary. In addition, the space time yield of continuous production 
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mode is usually higher than the batch production mode, application of a continuous 
reactor is relatively safer when compared to batch reactors. 
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9. FUTURE WORK 
 
This work is a preliminary attempt to use Dow’s F&EI in comparative study for 
pharmaceutical processes. Based on the challenges faced during this study, several 
opportunities can to be explored to continue the development in comparing the batch and 
continuous process:  
1. This research only studies the separate reactor with potential fire, explosion, and 
reactivity incidents. To get a more comprehensive comparison, which should be made 
for the whole process and considers all kinds of potential risks, the hazard and 
operability studies (HAZOP) are necessary for both batch and continuous 
pharmaceutical processes. 
2. For both case studies, abrupt transitions appear in F&EI that correspond to gradually 
changing inventory. In fact, these abrupt transitions are not reasonable and cannot be 
explained by the real production. Therefore, to get a more accurate evaluation in 
sensitivity, more data surrounding the transition points needs to be collected to 
understand the real situations at the critical points. 
3. Dow’s F&EI primarily focuses on the large scale bulk chemical and petrochemical 
productions. Its objectives determine that this methodology is relatively insusceptible 
in evaluation of pharmaceutical processes with low scale. For further studies in 
comparisons between batch and continuous process within the pharmaceutical 
industry, modifications in judgement of Dow’s F&EI are necessary. These 
adjustments can make the comparison results more accurate and reasonable. 
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4. The Dow’s F&EI evaluation is on the foundation of the most hazardous normal 
operation state. It attempts to determine the maximum loss for the given process. 
Therefore, only consequence analysis is covered by this methodology. More 
information on frequency analysis needs to be combined in the future work for an 
integrative risk assessment. 
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